These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 27004496)

  • 21. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-coated stent implantation vs. bypass surgery for in-stent occlusion after femoropopliteal stenting.
    Tomoi Y; Soga Y; Okazaki J; Iida O; Shiraki T; Hiramori S; Ando K
    Heart Vessels; 2021 May; 36(5):646-653. PubMed ID: 33392645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.
    Shammas NW; Shammas GA; Banerjee S; Popma JJ; Mohammad A; Jerin M
    J Endovasc Ther; 2016 Apr; 23(2):339-46. PubMed ID: 26921281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Yokoi H; Uematsu M;
    J Vasc Surg; 2016 Dec; 64(6):1691-1695.e1. PubMed ID: 27575807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.
    Ho KJ; Devlin PM; Madenci AL; Semel ME; Gravereaux EC; Nguyen LL; Belkin M; Menard MT
    J Vasc Surg; 2017 Mar; 65(3):734-743. PubMed ID: 27986482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.
    Laird JR; Katzen BT; Scheinert D; Lammer J; Carpenter J; Buchbinder M; Dave R; Ansel G; Lansky A; Cristea E; Collins TJ; Goldstein J; Cao AY; Jaff MR;
    J Endovasc Ther; 2012 Feb; 19(1):1-9. PubMed ID: 22313193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents.
    Chan YC; Cheng SW; Ting AC; Cheung GC
    J Vasc Surg; 2014 Feb; 59(2):384-91. PubMed ID: 24461862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Midterm Patency After Femoropopliteal Interventions: A Comparison of Standard and Interwoven Nitinol Stents and Drug-Coated Balloons in a Single-Center, Propensity Score-Matched Analysis.
    Steiner S; Schmidt A; Bausback Y; Piorkowski M; Werner M; Yahiaoui-Doktor M; Banning-Eichenseer U; Scheinert D
    J Endovasc Ther; 2016 Apr; 23(2):347-55. PubMed ID: 26848131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
    Liistro F; Angioli P; Porto I; Ricci L; Ducci K; Grotti S; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2014 Feb; 21(1):1-8. PubMed ID: 24502477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial.
    Jongsma H; van Mierlo-van den Broek P; Imani F; van den Heuvel D; de Vries JPM; Fioole B
    J Vasc Surg; 2017 Oct; 66(4):1293-1298. PubMed ID: 28826727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.